Management of H. pylori-Negative Mild Chronic Gastritis with Dyspepsia
Start empirical acid suppression therapy with a proton pump inhibitor (PPI) at the lowest effective dose, combined with lifestyle modifications including regular aerobic exercise. 1
Diagnosis and Current Status
Your endoscopy results show:
- Mild chronic gastritis in the antrum (H. pylori-negative)
- Normal duodenal mucosa (excluding celiac disease)
- No premalignant changes (no atrophy, intestinal metaplasia, or dysplasia)
This presentation is consistent with functional dyspepsia (FD) - a disorder of gut-brain interaction where symptoms persist despite normal or minimal endoscopic findings. The mild chronic gastritis without H. pylori is unlikely to be the primary driver of your symptoms 1.
First-Line Treatment Approach
1. Proton Pump Inhibitors (PPIs)
- PPIs are the most strongly recommended first-line pharmacological treatment for H. pylori-negative functional dyspepsia 1
- Use the lowest dose that controls symptoms (no dose-response relationship exists)
- Trial for 4-8 weeks initially
- Well-tolerated with high-quality evidence supporting efficacy
2. Lifestyle Modifications
- Regular aerobic exercise is strongly recommended for all FD patients 1
- This has a strong recommendation despite very low quality evidence, reflecting expert consensus on benefit
3. Alternative First-Line Options
If PPIs are ineffective or not tolerated:
- H2-receptor antagonists (e.g., famotidine) - reasonable alternative, well-tolerated 1
- Prokinetics (if available in your region) - efficacy varies by drug class; tegaserod has strongest evidence 1
Addressing Throat Discomfort
The throat discomfort may represent:
- Laryngopharyngeal reflux - PPIs address this mechanism
- Globus sensation - often coexists with functional dyspepsia
- Consider ENT evaluation if throat symptoms persist despite PPI therapy
Second-Line Treatment (If First-Line Fails After 8 Weeks)
Tricyclic antidepressants (TCAs) as gut-brain neuromodulators 1:
- Start amitriptyline 10 mg once daily at bedtime
- Titrate slowly to 30-50 mg daily as tolerated
- Explain these work on pain processing, not as antidepressants
- Strong recommendation with moderate-quality evidence
- Counsel about side effects (dry mouth, drowsiness, constipation)
Important Caveats
What NOT to Do:
- Avoid routine gastric emptying studies or 24-hour pH monitoring - not indicated for typical FD 1
- Avoid opioids - risk of iatrogenic harm outweighs benefit 1
- Avoid long-term continuous drug therapy - use intermittent short courses as needed 2
When to Escalate Care:
Refer to gastroenterology if:
- Symptoms are severe or refractory to first and second-line treatments
- Diagnostic doubt persists
- Patient requests specialist opinion 1
Red Flags Already Excluded:
Your biopsies have ruled out:
- Celiac disease (normal duodenal histology)
- H. pylori infection
- Gastric premalignant conditions (no atrophy, metaplasia, or dysplasia) 3, 4
The Mild Chronic Gastritis Finding
The mild chronic gastritis without H. pylori seen on your biopsy is:
- A common incidental finding in dyspeptic patients 5, 6
- May represent reactive gastropathy from bile reflux, NSAIDs, or other irritants 5, 7
- Does not require specific treatment beyond the functional dyspepsia management outlined above
- Not a premalignant condition in the absence of atrophy or intestinal metaplasia
Practical Algorithm
- Start low-dose PPI (e.g., omeprazole 20 mg daily or equivalent) + regular aerobic exercise
- Trial for 4-8 weeks
- If inadequate response → Add or switch to TCA (amitriptyline 10 mg, titrate to 30-50 mg)
- If still refractory → Gastroenterology referral for multidisciplinary management including potential psychological therapies 1
The key message: Your biopsies show reassuring findings with no serious pathology. This is functional dyspepsia requiring symptom-based management, not disease-specific treatment.